奥锐特(605116)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

605116 奥锐特

已收盘 05-11 15:00:00

{"stockData":{"symbol":"605116","market":"SH","secType":"STK","nameCN":"奥锐特","latestPrice":22.62,"timestamp":1778482802000,"preClose":22.87,"halted":0,"volume":4253500,"delay":0,"changeRate":-0.0109,"floatShares":405999999,"shares":405999999,"eps":0.9694,"marketStatus":"已收盘","change":-0.25,"latestTime":"05-11 15:00:00","open":22.95,"high":22.95,"low":22.41,"amount":96180400,"amplitude":0.0236,"askPrice":22.63,"askSize":133,"bidPrice":22.62,"bidSize":399,"shortable":0,"etf":0,"ttmEps":0.9694,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778549400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.87,"symbolType":"stock","openAndCloseTimeList":[[1778463000000,1778470200000],[1778475600000,1778482800000]],"highLimit":25.16,"lowLimit":20.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":406183234,"isCdr":false,"pbRate":3.4,"roa":"--","peRate":23.334021,"roe":"2.38%","epsLYR":1.12,"committee":-0.02844,"marketValue":9188000000,"turnoverRate":0.0105,"status":1,"floatMarketCap":9188000000},"requestUrl":"/m/hq/s/605116/tweets","defaultTab":"tweets","newsList":[{"id":"2634405979","title":"奥锐特(605116.SH)：多替拉韦钠片获得药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2634405979","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634405979?lang=zh_cn&edition=full","pubTime":"2026-05-11 15:40","pubTimestamp":1778485243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥锐特(605116.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的多替拉韦钠片《药品注册证书》，多替拉韦钠片适应症为联合其它抗逆转录病毒药物，用于治疗人类免疫缺陷病毒(HIV)感染的成人和年满12岁的儿童患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633346126","title":"奥锐特（605116）披露2025年年度股东会决议公告，5月7日股价上涨1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633346126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633346126?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:37","pubTimestamp":1778164632,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，奥锐特报收于23.14元，较前一交易日上涨1.27%，最新总市值为93.99亿元。该股当日开盘23.0元，最高23.34元，最低22.75元，成交额达9166.79万元，换手率为0.98%。近日，奥锐特药业股份有限公司披露《2025年年度股东会决议公告》。出席会议的股东所持表决权股份占公司总股本的71.3202%，所有议案均获通过，无否决议案。国浩律师（杭州）事务所对本次会议出具了法律意见书，认为会议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629406890","title":"异动快报：奥锐特（605116）4月24日14点49分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2629406890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629406890?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:50","pubTimestamp":1777013427,"startTime":"0","endTime":"0","summary":"证券之星4月24日盘中消息，14点49分奥锐特（605116）触及跌停板。其所属行业化学制药目前上涨。领涨股为金石亚药。该股为化学原料药，合成生物，医药概念热股。4月23日的资金流向数据方面，主力资金净流入465.63万元，占总成交额3.85%，游资资金净流出668.83万元，占总成交额5.52%，散户资金净流入203.2万元，占总成交额1.68%。近5日资金流向一览见下表：奥锐特主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400041954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629383999","title":"奥锐特(605116.SH)发布一季度业绩，归母净利润6393万元，同比下降46.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629383999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629383999?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:06","pubTimestamp":1776946019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥锐特(605116.SH)披露2026年第一季度报告，报告期公司实现营收3.89亿元，同比下降3.17%;归母净利润6393万元，同比下降46.47%;扣非净利润5857万元，同比下降48.16%。基本每股收益0.16元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628104746","title":"奥锐特（605116）披露保荐总结报告书，4月20日股价下跌1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628104746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628104746?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:32","pubTimestamp":1776677548,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘，奥锐特报收于27.12元，较前一交易日下跌1.6%，最新总市值为110.16亿元。近日，国泰海通证券股份有限公司发布《关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券并上市之保荐总结报告书》。公告显示，国泰海通证券作为奥锐特向不特定对象发行可转换公司债券的保荐机构，在持续督导期届满后出具该报告书。期间保荐机构履行了尽职推荐和持续督导职责，未发现重大违规事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000024471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627997602","title":"奥锐特最新公告：2025年净利润4.49亿元同比增长26.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627997602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627997602?lang=zh_cn&edition=full","pubTime":"2026-04-16 18:10","pubTimestamp":1776334258,"startTime":"0","endTime":"0","summary":"奥锐特(605116.SH)发布2025年年度报告，实现营业收入16.97亿元，同比增长15.03%；归属于上市公司股东的净利润为4.49亿元，同比增长26.61%。公司拟向全体股东每10股派发现金红利3.40元(含税)，不送红股，不进行资本公积转增。注：公司Q4净利润0.96亿，Q3净利润1.19亿，据此计算，Q4净利润环比下降19%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600035384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624507209","title":"奥锐特（605116）披露可转债转股结果暨股份变动公告，4月2日股价下跌1.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624507209","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624507209?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:38","pubTimestamp":1775140695,"startTime":"0","endTime":"0","summary":"奥锐特药业股份有限公司于2026年4月2日发布《关于可转债转股结果暨股份变动公告》。公告显示，截至2026年3月31日，累计已有面值34,000元“奥锐转债”转为公司A股普通股，累计转股1,353股，占转股前总股本的0.0003%。2026年1月1日至3月31日，有25,000元可转债转股，转股数量为1,000股，全部使用回购库存股转股，未新增股份。期间因回购注销离职员工限制性股票，总股本减少12,000股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200042758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623331781","title":"奥锐特：3月27日董事褚义舟减持股份合计65万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623331781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623331781?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:01","pubTimestamp":1774872114,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月30日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2026年3月27日公司董事褚义舟共减持公司股份65.0万股，占公司总股本为0.16%。变动期间公司股价上涨6.63%，3月27日当日收盘报26.68元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000031469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621269085","title":"股市必读：奥锐特（605116）3月23日收盘跌6.01%，主力净流出1234.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621269085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621269085?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:15","pubTimestamp":1774289715,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，奥锐特报收于24.38元，下跌6.01%，换手率1.38%，成交量5.61万手，成交额1.39亿元。当日关注点来自交易信息汇总：奥锐特股价连续4日下跌，3月23日收跌6.01%，报24.38元，当日主力资金净流出1234.37万元。来自交易信息汇总：该股前10个交易日主力资金累计净流入1.16亿元，期间股价累计下跌5.34%。资金流向3月23日主力资金净流出1234.37万元，占总成交额8.89%；游资资金净流入380.42万元，占总成交额2.74%；散户资金净流入853.95万元，占总成交额6.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400002052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621799676","title":"每周股票复盘：奥锐特（605116）获恩扎卢胺片药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2621799676","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621799676?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:51","pubTimestamp":1774119068,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，奥锐特报收于25.94元，较上周的25.7元上涨0.93%。本周关注点公司公告汇总：奥锐特获恩扎卢胺片药品注册批件，用于多种前列腺癌治疗。2026年3月16日，褚义舟减持45.0万股，占总股本0.1108%，当日收盘价26.51元，期间股价上涨3.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620242073","title":"奥锐特：3月16日董事褚义舟减持股份合计45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242073","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620242073?lang=zh_cn&edition=full","pubTime":"2026-03-17 21:24","pubTimestamp":1773753862,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月17日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特(605116)最新董监高及相关人员股份变动情况：2026年3月16日公司董事褚义舟共减持公司股份45.0万股，占公司总股本为0.1108%。变动期间公司股价上涨3.15%，3月16日当日收盘报26.51元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：    奥锐特的高管列表及最新持股情况如下：    该股最近90天内共有3家机构给出评级，买入评级3家。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/17/20260317292299.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/17/20260317292299.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260317/32075809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619046164","title":"奥锐特（605116）披露获得恩扎卢胺片药品注册批件，3月16日股价上涨3.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619046164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619046164?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:20","pubTimestamp":1773670840,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，奥锐特报收于26.51元，较前一交易日上涨3.15%，最新总市值为107.68亿元。奥锐特药业股份有限公司近日收到国家药品监督管理局核准签发的两份恩扎卢胺片《药品注册证书》，批准该药品用于转移性激素敏感性前列腺癌、非转移性去势抵抗性前列腺癌及转移性去势抵抗性前列腺癌成年患者的治疗。该产品获批符合药品注册要求，但后续生产销售仍受政策、市场等因素影响，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600036682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619507774","title":"奥锐特：3月13日董事褚义舟减持股份合计46万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619507774","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619507774?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:01","pubTimestamp":1773662507,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月16日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2026年3月13日公司董事褚义舟共减持公司股份46.0万股，占公司总股本为0.1132%。变动期间公司股价上涨0.27%，3月13日当日收盘报25.7元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有3家机构给出评级，买入评级3家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600031659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619643042","title":"奥锐特(605116.SH)：恩扎卢胺片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619643042","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619643042?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:47","pubTimestamp":1773647264,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥锐特(605116.SH)公告，公司收到国家药品监督管理局核准签发的两份恩扎卢胺片《药品注册证书》。公告显示，恩扎卢胺是第二代雄激素受体(AR)抑制剂，对AR具有更高的亲和力。它不仅能够有效阻断双氢睾酮与AR的结合，还能进一步抑制AR的核易位及其与DNA的转录结合，从而更彻底地阻断雄激素受体信号通路。该药物作用具有高特异性，仅拮抗AR，不会引起雄激素撤退综合征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥锐特(605116.SH)：恩扎卢胺片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619944611","title":"奥锐特：3月12日董事褚义舟减持股份合计29万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619944611","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619944611?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:01","pubTimestamp":1773403310,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月13日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2026年3月12日公司董事褚义舟共减持公司股份29.0万股，占公司总股本为0.0714%。变动期间公司股价下跌0.66%，3月12日当日收盘报25.63元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有3家机构给出评级，买入评级3家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300036475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131203","title":"奥锐特：3月11日董事褚义舟减持股份合计35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131203","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618131203?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:01","pubTimestamp":1773316893,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月12日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2026年3月11日公司董事褚义舟共减持公司股份35.0万股，占公司总股本为0.0862%。变动期间公司股价下跌1.23%，3月11日当日收盘报25.8元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有3家机构给出评级，买入评级3家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200034652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618553859","title":"奥锐特：3月9日董事褚义舟减持股份合计28.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618553859","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618553859?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:12","pubTimestamp":1773148321,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月10日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特(605116)最新董监高及相关人员股份变动情况：2026年3月9日公司董事褚义舟共减持公司股份28.5万股，占公司总股本为0.0702%。变动期间公司股价上涨0.9%，3月9日当日收盘报25.75元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：    奥锐特的高管列表及最新持股情况如下：    该股最近90天内共有3家机构给出评级，买入评级3家。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/10/20260310438523.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/10/20260310438523.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260310/32058166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618255086","title":"奥锐特：3月6日高管褚义舟减持股份合计32万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618255086","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618255086?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:02","pubTimestamp":1773057722,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月9日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2026年3月6日公司董事褚义舟共减持公司股份32.0万股，占公司总股本为0.0788%。变动期间公司股价上涨2.28%，3月6日当日收盘报25.52元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有3家机构给出评级，买入评级3家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900030529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617427885","title":"奥锐特：3月4日高管褚义舟减持股份合计1100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617427885","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617427885?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:46","pubTimestamp":1772714782,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月5日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特(605116)最新董监高及相关人员股份变动情况：2026年3月4日公司董事褚义舟共减持公司股份1100.0股，占公司总股本为0.0003%。变动期间公司股价下跌1.36%，3月4日当日收盘报24.66元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：    奥锐特的高管列表及最新持股情况如下：    该股最近90天内共有3家机构给出评级，买入评级3家。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/05/20260305264513.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/05/20260305264513.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260305/32047863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616532068","title":"奥锐特：3月3日高管褚义舟减持股份合计15.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616532068","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616532068?lang=zh_cn&edition=full","pubTime":"2026-03-04 20:01","pubTimestamp":1772625703,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月4日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2026年3月3日公司董事褚义舟共减持公司股份15.4万股，占公司总股本为0.0379%。变动期间公司股价下跌2.08%，3月3日当日收盘报25.0元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有3家机构给出评级，买入评级3家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400036360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778487508267,"stockEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":-0.1981},{"period":"3month","weight":-0.1717},{"period":"6month","weight":0.0013},{"period":"1year","weight":0.0983},{"period":"ytd","weight":-0.087}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0281},{"period":"6month","weight":0.0456},{"period":"1year","weight":0.247},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"奥锐特药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15779人(较上一季度增加68.35%)","perCapita":"25742股","listingDate":"2020-09-21","address":"浙江省台州市天台县八都工业园区","registeredCapital":"40618万元","survey":"　　奥锐特药业股份有限公司的主营业务是特色复杂原料药、医药中间体和制剂的研发、生产和销售。公司的主要产品是原料药及中间体、成品药、贸易类产品。近年来，公司不断推动科技创新和产业创新深度融合，培育发展新质生产力，打造高端医药制造能力，努力提升产品质量、成本控制、稳定供应等方面的综合竞争优势，实现高质量发展。公司2025年度被评为浙江省高新技术企业创新能力500强；Aurisco®获浙江出口名牌证书。2025年度扬州奥锐特获评江苏省企业技术中心、江苏省先进智能工厂、江苏省新质生产力促进中心颁发的江苏省瞪羚企业称号。","listedPrice":8.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥锐特(605116)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥锐特(605116)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥锐特,605116,奥锐特股票,奥锐特股票老虎,奥锐特股票老虎国际,奥锐特行情,奥锐特股票行情,奥锐特股价,奥锐特股市,奥锐特股票价格,奥锐特股票交易,奥锐特股票购买,奥锐特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥锐特(605116)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥锐特(605116)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}